Infection and Immunity, April 2000, p. 2069-2076, Vol. 68, No. 4
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Department of Medicine, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0560, and Veterans Affairs Hospital, Cincinnati, Ohio 48229
Received 11 October 1999/Returned for modification 2 December 1999/Accepted 4 January 2000
| |
ABSTRACT |
|---|
|
|
|---|
Histoplasma capsulatum induces a cell-mediated immune response in lungs and lymphoid organs of mammals. Resolution of primary infection in mice depends on interleukin-12 (IL-12), since neutralization of this monokine increases susceptibility to infection. The present study was designed to determine if blockade of IL-12 disrupts the protective immune response by altering the influx of lineage-specific cells into infected lungs and the numbers of cells expressing CD80, CD86, CD119, and major histocompatibility complex class II (MHC II) molecules. In mice given anti-IL-12, there was a 2.5-fold decrease in total numbers of T cells on days 3 to 10 of infection and a 4-fold increase in Mac-1/Gr-1+ cells on days 7 and 10 compared to infected controls. CD80+ lung cells from anti-IL-12-treated mice were 2- to 3-fold greater than those from controls on days 7 and 10, whereas the total numbers of CD86+ cells were 2- to 3-fold less and MHC II+ cells were 1.5- to 2-fold less on days 3 and 5. Cells expressing CD119 were reduced 1.5-fold on day 5. Treatment with monoclonal antibodies (MAb) to CD80, CD86, or both reduced the fungal burden slightly compared to that in rat immunoglobulin G-treated controls, whereas after IL-12 neutralization, blocking of CD80 reduced the tissue burden by 2.5-fold and this correlated with a decrease in IL-4. Regardless, mortality was not altered by treatment with MAb to CD80 or CD86. We conclude that (i) IL-12 neutralization alters the nature of the inflammatory response in lungs and the expression of CD80 and CD86 on lineage-specific cells, (ii) the immune response during infection with H. capsulatum is controlled via mechanisms independent of the CD80 and CD86 costimulatory pathways, and (iii) decreased expression of CD86 and MHC II may modulate generation of optimal protective immunity.
| |
INTRODUCTION |
|---|
|
|
|---|
Histoplasma capsulatum is
an intracellular pathogenic fungus that is responsible for mild disease
in immunocompetent hosts and a progressive and fatal disease if
untreated in immunocompromised hosts (7). The initial site
of infection is the lung, where yeast cells, produced from inhaled
microconidia, are ingested by alveolar macrophages (M
) via an
interaction between the CD11/CD18 family of adhesion molecules and
yeast cell wall components (4). Phagocytosis of yeast cells
by M
results in a permissive environment for survival and
replication of yeasts. Resistance to H. capsulatum infection
in mammals is primarily dependent on a cellular immune response
mediated by T cells and phagocytes. Resolution of infection in mice
requires the production of cytokines, especially gamma interferon
(IFN-
) (1, 30, 33), and release of this cytokine by NK
and T cells is dependent on the pathogen-induced release of the
monokine interleukin-12 (IL-12) (26). H. capsulatum infection of mice with a genetic absence of IFN-
or
those given antibodies (Ab) to IL-12 results in an uncontrollable and
fatal fungal burden (1, 2, 33). IL-12 release is necessary
for M
to kill yeasts before day 5 of infection, since animals
depleted of IL-12 beyond this point survive the infection
(1).
The purpose of this study was to determine if neutralization of IL-12
and subsequent IFN-
depletion altered the expression of cell surface
molecules involved in the generation of protective cell-mediated
immunity. The molecules CD80, CD86, major histocompatibility complex
class II (MHC II), and CD119 (IFN-
receptor) were chosen for
analysis because of their potential contribution to an effector cell-mediated immune response to H. capsulatum. We assessed
if blockade of IL-12 altered the number of cells that express these molecules and their surface density.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Mice. Male C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine) and maintained in the animal facility at the University of Cincinnati. All experiments used animals that were 6 to 12 weeks of age. Control and infected mice were housed in laminar flow units. Athymic nude mice were purchased from the National Cancer Institute (Frederick, Md.).
Preparation of yeast cultures and i.n. infection of mice. H. capsulatum yeast cells (strain G217B) were grown in 50 ml of Ham's F-12 medium supplemented with glucose (18.2 g/liter), glutamic acid (1 g/liter), HEPES (6 g/liter), and cysteine (8.4 mg/liter) for 48 h at 37°C. Cell suspensions were prepared by two washes with Hanks' balanced salt solution (HBSS) containing 0.2 M HEPES and 0.5% bovine serum albumin (BSA) followed by a third wash at 100 × g. The final volume was adjusted to equal 2.5 × 106 or 0.6 × 106 yeast cells per 50 µl of buffer. Mice anesthetized with Metophane (Pitman-Moore, Mundelein, Ill.) were infected intranasally (i.n.) with 50 µl of yeast suspension. Control animals were given equal volumes of buffer alone.
Enumeration of yeast burden in infected tissues. Spleens and lungs from mice were removed at selected intervals during infection and homogenized in 10 ml HBSS, and 100-µl portions of serial dilutions were streaked onto 150-mm-diameter plates containing 3.7% brain heart infusion (Difco, Detroit, Mich.), 1% glucose, 0.01% cysteine hydrochloride (Sigma, St. Louis, Mo.), 2% agar (Difco), 5 mg of gentamicin (Sigma) per ml, and 5% defibrinated sheep erythrocytes (Colorado Serum Co., Denver, Colo.). Plates were incubated at 30°C, and CFU were enumerated after 7 days.
Ab and immunofluorescent reagents.
Fluorescein
isothiocyanate (FITC)-conjugated monoclonal Ab (MAb) to CD45 (clone
30F11.1), CD45R/B220 (clone RA3-6B2), CD90.2 (Thy-1, clone 30-H12), and
Ly-6G/Gr-1 (clone RB6-8C5); biotin-conjugated MAb to CD119 (IFN-
receptor, clone GR20), CD86 (clone GL-1), and anti-mouse
I-Ab (clone AF6-120.1); phycoerythrin-conjugated CD80
(clone IG-10); and streptavidin-phycoerythrin (SAv-PE) were purchased
from Pharmingen (San Diego, Calif.). Ab produced by the anti-Mac-1
hybridoma (anti-CR3, clone M1/70) was purified from tissue culture
supernatant with a protein G affinity column (Pharmacia, Piscataway,
N.J.) and conjugated to FITC as previously reported (13).
Purification of Ab for depletion experiments.
Rat hybridomas
producing MAb to murine CD80 (B7-1, clone IG-10) and CD86 (B7-2, clone
GL-1) were purchased from the American Type Culture Collection,
Rockville, Md. Purification was accomplished by passing tissue culture
supernatants over an anti-bovine immunoglobulin (Ig) Sepharose column
in tandem with a protein G (Pharmacia) affinity column, followed by
elution with 0.1 M glycine-HCl, pH 2.8. After concentration, the Ab was
dialyzed against HBSS and filter sterilized. Alternatively, hybridoma
cells were injected into pristane-primed nude mice, and ascites fluid
was collected and purified by the capryllic acid-ammonium sulfate
method (16). Purified Ab was dialyzed against HBSS, filter
sterilized, and stored at
20°C until use. Ab against murine IL-12
(clones 15.1 and 15.6) were prepared as previously described
(1).
Treatment of mice with MAb. For IL-12 neutralization studies, mice were injected intraperitoneally with a mixture of 250 µg each of MAb 15.1 and 15.6 1 day before infection and on days 1, 3, 7, and 14 of infection as previously described (1). For experiments designed to examine the effects of CD80 and CD86 blockade, animals were injected i.n. with 200 µg of either anti-CD80 or anti-CD86 or a mixture of both in a final volume of 50 µl 1 day before infection and on days 1, 3, 5, 7, 10, 14, and 17 of infection. This dose of MAb has been reported to block function (27).
Determination of cytokine levels in infected lungs.
Tissue
homogenates or single-cell suspensions from lungs of infected animals
used for CFU analyses were centrifuged at 700 × g for
10 min, and supernatants were collected and stored at
70°C until
use. Enzyme-linked immunosorbent assay kits for the detection of
IFN-
, IL-4, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and tumor necrosis factor alpha (TNF-
) were purchased from
Endogen (Woburn, Mass.), and analysis was performed according to the
manufacturer's instructions.
Preparation of single-cell suspension from lung tissue. Lungs from infected animals were removed on days 3, 5, 7, 10, 14, and 21 of infection, initially crushed with a 10-ml syringe plunger, teased apart with forceps, and suspended in RPMI medium containing glutamine (0.29 mg/ml), penicillin, streptomycin (100 U/ml, 100 mg/ml), and 10% fetal bovine serum. The organs were homogenized into single-cell suspensions by sequential passage through 16-, 18-, and 20-gauge needles. The mononuclear fraction was isolated by separation on 40 to 70% Percoll gradients (Pharmacia). For surface phenotyping, cells were resuspended in phosphate-buffered saline (pH 7.3) containing 1% BSA and 0.1% azide.
Cell surface phenotype. Cells isolated from lungs were pelleted (1 × 105 to 5 × 105) at 350 × g and incubated with a saturating amount of Ab for 15 min at 4°C. Cells were washed twice with phosphate-buffered saline containing 1% BSA and 0.1% azide before addition of SAv-PE for biotinylated reagents followed by incubation and washing as before. For two-color analyses, cells were incubated with FITC-conjugated lineage-specific MAb, washed, and then incubated with phycoerythrin-conjugated CD80 or CD86-biotin and SAv-PE and then washed as before. All samples were resuspended in a 1% paraformaldehyde solution before analysis on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, Calif.). Flow cytometry data, reported as percent positive cells and mean fluorescence intensity (MFI), were determined with Cell Quest analysis software. Changes in the density of surface antigens can be determined by flow cytometry by measuring MFI values. In order to compare data from several experiments, these values were calculated as the fold increase in fluorescence intensity of the positive population over the MFI of the negative cells. This analysis corrects for variations in baseline values that fluctuate because of autofluorescence or nonspecific MAb interactions.
The absolute number of cells expressing each surface marker was calculated by multiplying the percent positive cells of each phenotype by the total number of cells derived from the Percoll gradients. Since cell types other than blood lineage cells were present within analysis gates that contained the total population of live cells, the data were normalized to represent hemopoietic lineage cells within the gate by multiplying by the percentage of CD45+ cells. This Ab (clone 30F11.1) recognizes all blood cells except erythrocytes (22).Statistical analyses. Student's t test was used to analyze differences in total numbers of cells expressing a certain phenotype, fungal burdens, and cytokine levels.
| |
RESULTS |
|---|
|
|
|---|
Enumeration of cells isolated from infected lungs.
The total
cell numbers in lungs of anti-IL-12-treated mice that were infected
with 2.5 × 106 yeasts were significantly greater than
those in control animals on days 7 and 10 of infection (P
0.01 and 0.02, respectively) (Table
1). The total numbers of cells from
anti-IL-12-treated animals after day 10 were not available, since 100%
of these animals succumbed to infection and died before day 14. The
mean survival time for these mice was 13.1 ± 0.9 days.
|
Analysis of cells expressing phenotypic markers in lungs of
control and anti-IL-12-treated mice.
Lungs from infected mice
treated with anti-IL-12 or rat IgG were removed on days 3, 5, 7, 10, 14, and 21 of infection for controls (rat IgG) or through day 10 for
IL-12-neutralized animals and analyzed by flow cytometry for expression
of surface markers. The lymphocyte populations of cells were reduced in
numbers after IL-12 neutralization, whereas myeloid lineage cell
numbers increased (Fig. 1). A comparison
of the absolute numbers of T cells in lungs from rat Ig- and
anti-IL-12-treated mice revealed that this population of cells was
decreased 1.5- to 2.5-fold in the latter group. These reduced numbers
of T cells were significantly different from those for rat IgG controls
on all days analyzed (days 3, 5, 7, and 10; P
0.027,
0.008, 0.014, and 0.022, respectively). B cells also were significantly
less after IL-12 neutralization on day 5 (2.5-fold; P
0.046) and day 7 (3-fold; P
0.046) (data not
shown). After IL-12 neutralization a threefold increase in numbers of
myeloid-lineage cells in lungs was observed on days 7 and 10 of
infection (P
0.001 and P
0.033,
respectively), as well as a fourfold increase in Gr-1+
cells on day 7 (P
0.008) and fivefold greater
numbers on day 10 (P
0.05).
|
0.001) and day 10 (2.5-fold; P
0.004), whereas
the numbers of CD86+ cells were depressed by approximately
threefold on days 3 (P
0.01) and 5 (P
0.006) but were similar to control values by day 7 (Fig.
2).
|
0.024). The number of cells expressing MHC II molecules increased over those for noninfected mice in both rat IgG- and anti-IL-12-treated mice as infection progressed, but the MHC II+ cells
observed after IL-12 neutralization were significantly decreased
compared to those for controls on days 3 (2-fold; P
0.039), 5 (2.5-fold; P
0.010), and 7 (1.7-fold;
P
0.028).
Changes in cell surface densities of MHC II, CD80, and CD86
molecules.
Initially we determined if infection with H. capsulatum altered the relative densities of surface MHC II, CD80,
CD86, and Mac-1 molecules. To accomplish this, MFI values were compared between naive (noninfected) and rat IgG-treated mice on days 3, 5, 7, 10, 14, and 21 of infection. The densities of surface CD80 and Mac-1
molecules were similar in the two groups through day 7, whereas CD86
expression was increased approximately 2.5-fold on days 3 and 5 (P
0.05). The MFI for MHC II expression decreased three- to fourfold in the rat IgG-treated group when compared to
noninfected (naive) animals (P
0.02) on all days
analyzed. Therefore, no changes in surface expression of CD80 and Mac-1 were observed, CD86 expression increased, and MHC II expression decreased during the first week.
0.02). CD86 densities were significantly
decreased on lung cells isolated from anti-IL-12-treated mice on days
5, 7, and 10 (P
0.03), whereas surface expression of
Mac-1 was increased on all days analyzed (P
0.05).
Although the density measurements for MHC II differed between rat IgG-
and anti-IL-12-treated animals, none of these differences was
significant (P
0.05).
|
Cellular phenotype during reduced fungal burden.
It was
possible that the changes observed in cell surface phenotype after
IL-12 neutralization were caused by an increased fungal burden. To
address this hypothesis, mice treated with anti-IL-12 were infected
with an inoculum of H. capsulatum (0.6 × 106) that approximated the burden in control mice during
days 7 to 14. We did not include a group of rat IgG-treated animals
injected with 0.6 × 106 yeasts, since the purpose of
this experiment was to ascertain if the fungal burden or anti-IL-12
influenced the inflammatory response. The lungs of mice that received
the reduced number of yeasts and anti-IL-12 contained 1.91 × 106 ± 0.70 × 106 CFU on day 10 of
infection. This value was approximately the same (P
0.05) as that observed in controls on day 7 (2.4 × 106 ± 0.45 × 106).
|
0.045).
Distribution of CD80+ and CD86+ cells among
different cell lineages.
Since CD80 and CD86 are expressed by
multiple cell types, data from two-color immunofluorescent analyses of
surface expression of these molecules versus the lineage markers Thy-1
(T cells), B220 (B cells), Mac-1 (myeloid cells), and Gr-1
(granulocytes) were calculated as the total number of lineage-specific
cells that express these markers during histoplasmosis in control and IL-12-neutralized animals (Fig. 5). The
majority of CD80+ cells on day 3 of infection were
Mac-1+, and most coexpressed the granulocyte marker Gr-1.
This myeloid cell dominance for CD80+ cells continued
through day 7 and then declined as the number of CD80+ T
cells increased on days 10 and 14 of infection (Fig. 5A). The distribution of CD80+ cells in IL-12-depleted mice was
dramatically different (Fig. 5B). The large increase in
Mac-1+ and Gr-1+ cells that expressed CD80 was
delayed until after day 5 and peaked on day 7, when 25% of all
Mac-1+ cells in lungs coexpressed CD80. In contrast, cells
expressing both markers in controls on days 3 and 5 represented 10% of
the total Mac-1+ cells. Although the total T-cell
population on day 10 was increased after IL-12 neutralization, the
number of CD80+ T cells was greatly diminished (ninefold
less than controls) (Fig. 5B).
|
Effect of blocking CD80 and CD86 on fungal burden.
Since
both CD80 and CD86 were upregulated during infection with H. capsulatum and expression of these molecules was altered in
animals treated with anti-IL-12, we determined if blocking of either or
both of these CD28 ligands would alter the outcome of disease. Lungs
and spleens were removed from animals treated with rat IgG or MAb to
CD80, CD86, or both on days 7, 14, and 21 of infection, and the fungal
burden was determined by CFU analysis. Although there was a slight
decrease in the burden on day 7 in both spleens and lungs of all
groups, none of these values were significantly different from those
for controls treated with rat IgG (P
0.05) (Table
2).
|
0.01), by 2.5-fold, when CD80 was
blocked (Table 2).
To determine if modulation of cytokine levels correlated with the
reduction in CFU, supernatants from lungs of mice treated with rat IgG,
anti-IL-12, anti-CD80, or both anti-IL-12 and anti-CD80 were analyzed
for the amounts of IFN-
, IL-4, TNF-
, and GM-CSF (Table
3). TNF-
levels in the lungs were
similar among all groups. GM-CSF levels in all three experimental
groups were significantly decreased compared to those in infected
controls (P
0.005), but the values for
anti-CD80-treated, IL-12-neutralized, and anti-CD80- and
anti-IL-12-treated animals were comparable to each other. IL-4 levels
in lungs from control animals and IL-12-neutralized mice were not
significantly different, whereas treatment with anti-CD80 reduced IL-4
levels in both infected controls given rat IgG and mice given
anti-IL-12 (P
0.01 and P
0.03,
respectively). In addition, IL-4 levels in animals treated with both
antibodies were reduced compared with those in mice treated with IL-12
alone (P
0.006). IFN-
was slightly reduced when
CD80 was blocked (P
0.04), whereas cytokine levels
in the experimental groups given anti-IL-12 were four- to fivefold
decreased (P
0.007) compared to those in the rat
IgG-treated controls. The ratios of IFN-
to IL-4 were 1,030 and
1,070 for the control and anti-CD80-treated groups, respectively,
whereas these ratios were greatly reduced after IL-12 neutralization
(to 284 and to 330) when MAb to both IL-12 and CD80 were administered.
|
| |
DISCUSSION |
|---|
|
|
|---|
The principal goal of this study was to further explore the
effects of IL-12 neutralization in lungs of mice infected with H. capsulatum. Emphasis was placed on determining alterations in the
surface expression of molecules responsible for interactions between T
cells and antigen-presenting cells, namely, CD80, CD86, and MHC II, as
well as the IFN-
receptor (CD119). After IL-12 neutralization, there
were perturbations in the influx of myeloid and T cells and reductions
in the total numbers of cells that express CD86 and MHC II.
In association with the increased fungal burden in mice given MAb to IL-12, there was a dramatically different inflammatory response. Two major alterations in the lineage-cell distribution in lungs of IL-12-depleted mice were (i) the large increase of myeloid cells, especially polymorphonuclear leukocytes, into the lung after day 5 of infection and (ii) the almost complete absence of T-cell infiltration during the first week. The lack of endogenous IL-12 clearly modulated the evolution of the inflammatory response. That IL-12 influences pulmonary inflammation has been demonstrated in a model of cryptococcosis. Administration of exogenous IL-12 increases both mononuclear leukocyte infiltration into lungs of mice and the levels of the chemoattractants macrophage inflammatory protein-1 alpha and monocyte chemotactic protein 1 (14).
The T-cell influx in lungs of infected controls peaks during the second week of infection, while the numbers of myeloid cells decrease (5). After IL-12 neutralization, the expected rise in the number of T cells in lungs was not observed. The failure of these cells to migrate into infected lungs could have been caused by a disrupted chemokine response, since T-cell influx into inflammatory sites can be controlled by multiple chemokines and their receptors (29). Although evidence directly linking endogenous IL-12 generation and T-cell chemotaxis is scarce, one study reported that IL-12 upregulates E- and P-selectin ligands on T cells, thus facilitating recruitment into inflamed tissue (31).
IL-12 neutralization affected cells expressing CD80 and CD86
differently. The numbers of CD80+ cells were fourfold
greater on days 7 and 10, but the surface density was twofold less. The
differences in CD86+ cells were observed on days 3 and 5, when a threefold reduction in total numbers and a significant decrease
in surface density were detected after IL-12 neutralization. Since
there was a decrease in both the numbers of CD86+ cells and
their surface density, the availability of CD86 molecules for binding
to CD28 was definitely less than in controls. This reduction during the
first week indicated that expression of this molecule was influenced by
the IFN-
deficiency induced by administration of MAb to IL-12.
Since IFN-
is a potent stimulator of MHC II surface expression
(9, 12, 21), we tested the effect of IL-12 neutralization on
the number of cells that expressed MHC II and the density of expression. H. capsulatum infection produced a
downregulation in surface MHC II molecules on lung cells isolated from
rat Ig- and anti-IL-12-treated mice compared to noninfected controls. Although the number of MHC II-bearing cells in infected
anti-IL-12-treated mice was markedly less than that in infected
controls on days 3 to 7, there were no significant differences in MFI
values between the two groups. Therefore, decreased levels of IFN-
affected the numbers of MHC II+ cells but not the density
per cell. These data strongly suggest that IFN-
is not the sole
regulator of MHC II expression in H. capsulatum-infected
mice. TNF-
and GM-CSF, two other cytokines that stimulate MHC II
expression, may have compensated for the IFN-
deficiency (12,
21).
An important consideration for these studies was to determine if
the altered inflammatory response in mice administered anti-IL-12 and
injected with 2.5 × 106 yeasts was simply a
consequence of an increased fungal burden or the lack of IL-12 and
IFN-
. To address these issues, we designed an experiment in which
the CFU in lungs of infected controls would be commensurate with those
in mice receiving MAb to IL-12 during the early phases of infection
(
10 days). An inoculum size of 0.6 × 106 was
selected and given to mice treated with anti-IL-12. The marked elevations in myeloid cells that were observed in mice infected with
2.5 × 106 yeasts and given anti-IL-12 were not
apparent in the group injected with anti-IL-12 and the lower inoculum.
Likewise, the variation in the number of CD80+ and
CD86+ cells was no longer detected. For these cell
populations, the fungal burden stimulated the fluctuations. On the
other hand, the MHC II+ cell numbers were significantly
lower in the group receiving anti-IL-12 and the lower inoculum of
H. capsulatum. The decline in this cell population was
likely to be modified by the deficiency in IL-12 and IFN-
rather
than by a change in the number of yeasts recovered from lungs.
The influx of T cells appeared to be dependent on the fungal burden, since their numbers were similar when the burdens were matched (day 7 in infected controls and day 10 for mice anti-IL-12 treated and inoculated with 0.6 × 106 yeasts). Yet, the lungs of anti-IL-treated mice infected with 2.5 × 106 yeasts also contained similar numbers of T cells on day 10, when the CFU were fourfold greater. However, the subset distribution of T cells in this group of mice was altered. CD86+ Thy-1+ cells were decreased compared to those in infected controls and mice given anti-IL-12 and infected with 0.6 × 106 yeasts. It is possible that the large cellular influx triggered on day 10 in mice IL-12 neutralized and infected with 2.5 × 106 yeasts resulted in a transient migration of T cells and that their numbers are not as important as their phenotype.
There are conflicting data on the function of CD80 and CD86 in
promoting differentiation of a T-helper cell type 1 (Th1) versus a Th2
response. In experimental allergic encephalomyelitis (15) and bronchial asthma (27) the interaction between CD80 and
CD28 triggers differentiation of Th1 cells that produce IFN-
, and CD86 is responsible for generation of Th2 cells and IL-4 production. Subsequent data revealed that CD86-transfected CHO cells preferentially induce IL-4-producing cells (11) or that there is no skewing of T cells to a Th1 or Th2 phenotype by either CD80 or CD86
(19).
Studies have shown that induction of Th1 or Th2 cytokines in animals
given MAb to CD80 or CD86 varies with the model of infection. Blocking
of CD86 reduces IL-4 levels and the burden in mice infected with either
Leishmania major (3, 6) or Candida
albicans (17), whereas blocking of both CD80 and CD86
results in reduced IFN-
levels but has no effect on the burden of
Listeria monocytogenes (32). In experimental
schistosomiasis (28) and borreliosis (23) CD86
blockade reduces IL-4 levels, but it reduces the burden only during
schistosomiasis. A common factor in most of these disease models is
that inhibition of CD86 appears to reduce IL-4 levels. However,
administration of anti-CD86 increases the numbers of IL-4- and
IFN-
-secreting cells in mice infected with Leishmania donovani (18). In contrast, anti-CD80 treatment reduced
IL-4 levels in control and anti-IL-12-treated mice infected with
H. capsulatum. Thus, the effects of CD80 and CD86 on
cytokine production differ from those in other experimental models.
To determine if CD80 and CD86 influenced the course of disease, groups of infected mice were treated i.n. with MAb to these molecules that have been reported to block effector cell function (27). Treatment with MAb to CD80, CD86, or both reduced the burden only slightly compared to that in rat Ig-treated controls. Thus, blockade of CD80 and CD86 did not enhance an efficient host resistance mechanism. A significant decrease in burden was observed in animals treated with anti-CD80 and anti-IL-12. Under these conditions, the reduction in fungal burden was more dramatic, because host control of histoplasmosis was blunted in the presence of anti-IL-12, and the beneficial effect of CD80 blockade was observed only in a model where the host response is impaired. A similar result was reported for resistant mice infected with L. major (6). In this study the burden was slightly reduced after administration of CTLA4-Ig, a reagent that blocks both CD80 and CD86, but the greater effect was in the significant reduction of burden by the same treatment in susceptible mice.
Disease progression may be controlled by altering the relative
levels of cytokines that are required for healing and those that
exacerbate infection (8, 10, 24, 25). That the balance between Th1 and Th2 cytokines, rather than the absolute values, is
important for disease amelioration has been shown in a model of
leishmaniasis (20). Susceptable BALB/c mice that lack the IL-4 receptor alpha chain do not increase IFN-
levels over those in
wild-type animals, yet infection is partially controlled. This study
concludes that even low levels of IFN-
can have a healing effect in
the absence of IL-4. During histoplasmosis, anti-IL-12 treatment
changed the ratio of IFN-
to IL-4 but not the absolute levels of the
latter. The reduction in IL-4 caused by anti-CD80 treatment slightly
improved the balance between the two cytokines and, as a consequence,
partially restored host resistance. Regardless of any reduction in
burden observed, the outcome of disease was the same. In the presence
or absence of anti-CD80, anti-IL-12 recipients died with comparable
mean survival times. Therefore, the impact of CD80 blockade was
transient and failed to completely restore protective immunity.
The present study demonstrated that IL-12 neutralization and infection with H. capsulatum altered the inflammatory response by greatly enhancing the myeloid cell influx into mouse lungs and greatly reducing the T-cell population, the numbers of cells that express MHC II molecules, and the numbers and density of the costimulatory molecule CD86. Alterations in these two surface antigens, which function in antigen presentation and as a second signal for activation of T cells, respectively, were observed early in infection when the effects of anti-IL-12 treatment are detrimental. The CD86 costimulatory molecule was not entirely responsible for protective immunity but may be part of a mechanism of T-cell activation and recruitment necessary for establishing an adaptive immune response.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grants AI-42747 and AI-34361 and by a Merit Review Award from the Department of Veterans Affairs.
We thank George Brunner for excellent technical assistance and Simon Newman, Carlos Subauste, and Francisco Gomez for their critical review of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Internal Medicine, Division of Infectious Diseases, University of Cincinnati Medical Center, P.O. Box 670560, Cincinnati, OH 45267-0560. Phone: (513) 558-4704. Fax: (513) 558-2089. E-mail: deepegs{at}emailuc.edu.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Allendoerfer, R., G. P. Boivin, and G. S. Deepe, Jr. 1997. Modulation of immune responses in murine pulmonary histoplasmosis. J. Infect. Dis. 175:905-914[Medline]. |
| 2. | Allendoerfer, R., and G. S. Deepe, Jr. 1997. Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice. Infect. Immun. 65:2564-2569[Abstract]. |
| 3. | Brown, J. A., R. G. Titus, N. Nabavi, and L. H. Glimcher. 1996. Blockade of CD86 ameliorated Leishmania major infection by down-regulating the Th2 response. J. Infect. Dis. 174:1303-1308[Medline]. |
| 4. |
Bullock, W. E., and S. D. Wright.
1987.
Role of the adherence-promoting receptors, CR3, LFA-1, and p150,95, in binding of Histoplasma capsulatum by human macrophages.
J. Exp. Med.
165:195-210 |
| 5. |
Cain, J. A., and G. S. Deepe, Jr.
1998.
Evolution of the primary immune response to Histoplasma capsulatum in murine lungs.
Infect. Immun.
66:1473-1481 |
| 6. | Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Lockley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142-4148[Abstract]. |
| 7. | Deepe, G. S., Jr. 1994. The immune response to Histoplasma capsulatum: unearthing its secrets. J. Lab. Clin. Med. 123:201-205[Medline]. |
| 8. | Deepe, G. S., Jr., and R. A. Seder. 1998. Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res. Immunol. 149:397-406[CrossRef][Medline]. |
| 9. | Ding, L., P. S. Linsley, L. Huang, R. N. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-1234[Abstract]. |
| 10. | Erb, K. J., C. Blank, and H. Moll. 1996. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response. Immunol. Cell. Biol. 74:239-244[Medline]. |
| 11. | Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523-532[CrossRef][Medline]. |
| 12. | Glimcher, L. H., and C. J. Kara. 1992. Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol. 10:13-49[CrossRef][Medline]. |
| 13. | Goding, J. W. 1976. Conjugation of antibodies with fluorochromes: modification to the standard methods. J. Immunol. Methods 13:215-225[CrossRef][Medline]. |
| 14. | Kawakami, K., M. H. Qureshi, T. Zhang, Y. Koguchi, K. Shibuya, S. Naoe, and A. Saito. 1999. Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin. Exp. Immunol. 117:113-122[CrossRef][Medline]. |
| 15. | Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. M. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707-718[CrossRef][Medline]. |
| 16. | McKinney, M. M., and A. Parkinson. 1987. A simple non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J. Immunol. Methods 96:271-278[CrossRef][Medline]. |
| 17. |
Mencacci, A.,
E. Cenci,
G. Del Sero,
C. F. d'Ostiani,
P. Mosci,
G. Trinchieri,
L. Adorini, and L. Romani.
1998.
IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection.
J. Immunol.
161:6228-6237 |
| 18. | Murphy, M. L., C. R. Engwerda, P. M. A. Gorak, and P. M. Kaye. 1997. B7-2 blockade enhances T cell responses to Leishmania donovani. J. Immunol. 159:4460-4466[Abstract]. |
| 19. | Natesan, M., Z. Razi-Wolf, and H. Reiser. 1996. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J. Immunol. 156:2783-2791[Abstract]. |
| 20. |
Noben-Trauth, N.,
W. E. Paul, and D. L. Sacks.
1999.
IL-4 and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains.
J. Immunol.
162:6132-6140 |
| 21. |
Panek, R. B., and N. Benveniste.
1995.
Class II MHC gene expression in microglia. Regulation by the cytokines IFN- , TNF- , and TGF- .
J. Immunol.
154:2846-2854[Abstract].
|
| 22. | Scheid, M. P., and D. Triglia. 1979. Further description of the Ly-5 system. Immunogenetics 9:423-432[CrossRef]. |
| 23. |
Shanafelt, M. C.,
I. Kang,
S. W. Barthold, and L. K. Bockenstedt.
1998.
Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.
Infect. Immun.
66:266-271 |
| 24. |
Szalay, G.,
C. H. Ladel,
C. Blum, and S. H. E. Kaufmann.
1996.
IL-4 neutralization or TNF- treatment ameliorate disease by an intracellular pathogen in IFN- receptor-deficient mice.
J. Immunol.
157:4746-4750[Abstract].
|
| 25. | Tonnetti, L., R. Spaccepelo, E. Cenci, A. Mencacci, P. Puccetti, R. L. Coffman, F. Bistoni, and R. Romani. 1995. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur. J. Immunol. 25:1559-1565[Medline]. |
| 26. |
Trinchieri, G.
1997.
Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN- ).
Curr. Opin. Immunol.
9:17-23[CrossRef][Medline].
|
| 27. |
Tsuyuki, S.,
J. Tsuyuki,
K. Einsle,
M. Kopf, and A. J. Coyle.
1997.
Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness.
J. Exp. Med.
185:1671-1679 |
| 28. | Villanueva, P. O. F., H. Reiser, and M. J. Stadecker. 1994. Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. J. Immunol. 153:5190-5199[Abstract]. |
| 29. | Ward, S. G., and J. Westwick. 1998. Chemokines: understanding their role in T-lymphocyte biology. Biochem. J. 333:457-470. |
| 30. |
Wu-Hsieh, B.
1989.
Relative susceptibilities of inbred mouse strains C57BL/6 and A/J to infection with Histoplasma capsulatum.
Infect. Immun.
57:3788-3792 |
| 31. |
Xie, H.,
Y. C. Lim,
F. W. Luscinskas, and A. H. Lichtman.
1999.
Acquisition of selectin binding and peripheral homing properties by CD4(+) and CD8(+) T cells.
J. Exp. Med.
189:1765-1776 |
| 32. | Zhan, Y., and C. Cheers. 1996. Either B7-1 or B7-2 is required for Listeria monocytogenes-specific production of gamma interferon and interleukin-2. Infect. Immun. 64:5349-5441[Abstract]. |
| 33. |
Zhou, P.,
M. C. Sieve,
J. Bennett,
K. J. Kwon-Chung,
R. P. Tewari,
R. T. Gazzinelli,
A. Sher, and R. A. Seder.
1995.
IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN- .
J. Immunol.
155:785-795[Abstract].
|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|